Clinical trial
Anti-PD-1 Antibody Sintilimab Combined With Anti-angeogensis Inhibitor Anlotinib in Treatment of Extensive-stage Disease Small Cell Lung Cancer After Failure of First Line Standard Therapy : a Single-arm Prospective Phase II Clinical Study
NCT04967625 is registered in ClinicalTrials.gov with Zhejiang Cancer Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Anti-PD-1 Antibody Sintilimab Combined With Anti-angeogensis Inhibitor Anlotinib in Treatment of Extensive-stage Disease Small Cell Lung Cancer After Failure of First Line Standard Therapy : a Single-arm Prospective Phase II Clinical Study
- Lead sponsor
- Zhejiang Cancer Hospital
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- July 26, 2021
- Completion date
- December 31, 2023
- Enrollment
- 23 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
small cell lung cancer extensive stage